Vis enkel innførsel

dc.contributor.authorBender, Jennifer
dc.contributor.authorCattoir, Vincent
dc.contributor.authorHegstad, Kristin
dc.contributor.authorSadowy, Eva
dc.contributor.authorCoque, Teresa M.
dc.contributor.authorWesth, Henrik
dc.contributor.authorHammerum, Anette M.
dc.contributor.authorSchaffer, Kirsten
dc.contributor.authorBurns, Karen
dc.contributor.authorMurchan, Stephen
dc.contributor.authorNovais, Carla
dc.contributor.authorFreitas, Ana R.
dc.contributor.authorPeixe, Luísa
dc.contributor.authorDel Grosso, Maria
dc.contributor.authorPantosti, Annalisa
dc.contributor.authorWerner, Guido
dc.date.accessioned2019-05-14T12:59:25Z
dc.date.available2019-05-14T12:59:25Z
dc.date.issued2018-11-02
dc.description.abstractVancomycin-resistant enterococci (VRE) are important nosocomial pathogens. Invasive VRE infections are difficult to treat since common therapeutic options including ampicillin and glycopeptides often fail. In vitro, most VRE remain susceptible to last-resort antibiotics such as linezolid, tigecycline and daptomycin. However, neither tigecycline nor linezolid act in a bactericidal manner, and daptomycin has proven activity only at high dosages licensed for treating enterococcal endocarditis. Despite these pharmacological and therapeutic limitations, reports on resistance to these last-resort drugs in VRE, and enterococci in general, have increased in recent years. In this review, we briefly recapitulate the current knowledge on the mode of action as well as the known and novel mechanisms of resistance and describe surveillance data on resistance to linezolid, tigecycline and daptomycin in enterococci. In addition, we also suggest a common nomenclature for designating enterococci and VRE with resistances to these important last-resort antibiotics.en_US
dc.descriptionSource at <a href=https://doi.org/10.1016/j.drup.2018.10.002>https://doi.org/10.1016/j.drup.2018.10.002. </a>en_US
dc.identifier.citationBender, J.K., Cattoir, V., Hegstad, K., Sadowy, E., Coque, T.M., Westh, H. ... Werner, G. (2018). Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature. <i>Drug resistance updates, 40</i>, 25-39. https://doi.org/10.1016/j.drup.2018.10.002en_US
dc.identifier.cristinIDFRIDAID 1653767
dc.identifier.doi10.1016/j.drup.2018.10.002
dc.identifier.issn1368-7646
dc.identifier.issn1532-2084
dc.identifier.urihttps://hdl.handle.net/10037/15303
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.journalDrug resistance updates
dc.rights.accessRightsopenAccessen_US
dc.subjectvanAen_US
dc.subjectvanBen_US
dc.subjectVREen_US
dc.subjectLinezoliden_US
dc.subjectTigecyclineen_US
dc.subjectDaptomycinen_US
dc.subjectVDP::Medical disciplines: 700::Health sciences: 800::Community medicine, Social medicine: 801en_US
dc.subjectVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin, sosialmedisin: 801en_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.titleUpdate on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclatureen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel